ATE201596T1 - Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut - Google Patents

Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut

Info

Publication number
ATE201596T1
ATE201596T1 AT93918860T AT93918860T ATE201596T1 AT E201596 T1 ATE201596 T1 AT E201596T1 AT 93918860 T AT93918860 T AT 93918860T AT 93918860 T AT93918860 T AT 93918860T AT E201596 T1 ATE201596 T1 AT E201596T1
Authority
AT
Austria
Prior art keywords
target cells
cells
transcutane
blood
vivo activation
Prior art date
Application number
AT93918860T
Other languages
English (en)
Inventor
Anna M Richter
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Application granted granted Critical
Publication of ATE201596T1 publication Critical patent/ATE201596T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93918860T 1992-09-21 1993-09-20 Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut ATE201596T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94811392A 1992-09-21 1992-09-21
PCT/CA1993/000382 WO1994006424A1 (en) 1992-09-21 1993-09-20 Transcutaneous in vivo activation of photosensitive agents in blood

Publications (1)

Publication Number Publication Date
ATE201596T1 true ATE201596T1 (de) 2001-06-15

Family

ID=25487290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918860T ATE201596T1 (de) 1992-09-21 1993-09-20 Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut

Country Status (21)

Country Link
US (2) US5484803A (de)
EP (1) EP0660712B1 (de)
JP (2) JP3598306B2 (de)
AT (1) ATE201596T1 (de)
AU (1) AU681088B2 (de)
CA (1) CA2144327C (de)
DE (1) DE69330277T2 (de)
DK (1) DK0660712T3 (de)
ES (1) ES2160600T3 (de)
FI (1) FI951295A7 (de)
GR (1) GR3036479T3 (de)
HU (1) HU220251B (de)
IL (1) IL107035A (de)
NO (1) NO951066L (de)
NZ (1) NZ255302A (de)
PL (1) PL308116A1 (de)
PT (1) PT660712E (de)
SK (1) SK35295A3 (de)
TW (1) TW241204B (de)
WO (1) WO1994006424A1 (de)
ZA (1) ZA936968B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6710066B2 (en) * 1989-07-28 2004-03-23 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US20020058008A1 (en) * 1989-07-28 2002-05-16 Kennedy James C. Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5587490A (en) * 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5798238A (en) * 1990-04-16 1998-08-25 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US20040110819A1 (en) * 1991-10-28 2004-06-10 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
ATE189966T1 (de) * 1992-11-20 2000-03-15 Univ British Columbia Aktivierung von photoempfindlichen mitteln
EP0831909B1 (de) * 1995-06-05 2005-01-26 Queen's University at Kingston Verwendung eines protoporphyrin ix precursor zur behandlung von dermatophytosen und malaria nach photoaktivierung von diesem besagten protoporphyrin
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
ATE235814T1 (de) * 1995-11-06 2003-04-15 New York Blood Ct Inc Behandlung von roten blutzellen zur inaktivierung von virien durch verwendung von pathalocyanine und rotlicht
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
US6159733A (en) * 1996-06-20 2000-12-12 New York Blood Center, Inc. Method for photoinactivating malignant cells
US5922278A (en) † 1996-11-19 1999-07-13 Baxter International Inc. Method and apparatus for inactivating contaminants in biological fluid
US5742380A (en) * 1996-12-31 1998-04-21 Ronn Avigdor M Plasma assay spectrometer
US6010890A (en) * 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
US6103706A (en) * 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
US5856566A (en) 1997-09-02 1999-01-05 Dusa Pharmaceuticals, Inc. Sterilized 5-aminolevulinic acid
US6159178A (en) 1998-01-23 2000-12-12 Heartport, Inc. Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested
US6096066A (en) * 1998-09-11 2000-08-01 Light Sciences Limited Partnership Conformal patch for administering light therapy to subcutaneous tumors
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
JP2002534218A (ja) 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 非侵襲性の脈管療法
JP2002534483A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 代謝性骨障害または骨転移のための治療的組成物
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6376483B1 (en) 1999-05-27 2002-04-23 Miravant Pharmaceuticals, Inc. Bacteriochlorins and bacteriopurpurins useful as photoselective compounds for photodynamic therapy and a process for their production
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
DE19960705A1 (de) * 1999-12-16 2001-06-21 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur Herstellung eines autologen Immunisierungsimpfstoffes gegen Krebserkrankungen (Tumorvakzine)
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
EP1267935A2 (de) 2000-01-12 2003-01-02 Light Sciences Corporation Behandlung von augenerkrankungen
KR100365151B1 (ko) * 2000-05-08 2003-02-11 김형락 어류 병원성 세균과 바이러스의 감염 예방 및 치료를 위한δ-아미노레불린산의 신규한 용도
DE10034673C1 (de) 2000-07-17 2002-04-25 Medac Klinische Spezialpraep Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung
ATE463237T1 (de) 2000-08-16 2010-04-15 Gen Hospital Corp Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
EP2248536A3 (de) 2000-12-14 2010-12-08 The General Hospital Corporation doing business as Massachusetts General Hospital Topische aminolevulinsäure-photodynamische therapie für akne vulgaris
US7498029B2 (en) * 2001-05-01 2009-03-03 The General Hospital Corporation Photoimmunotherapies for cancer using combination therapies
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
DE10162712A1 (de) * 2001-12-19 2003-07-17 Blutspendienst Der Landesverba Verfahren zur Inaktivierung von Bakterien und Leukozyten in Blut oder Blutprodukten
US20030167033A1 (en) * 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20070020272A1 (en) * 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
JP2007500227A (ja) * 2003-05-29 2007-01-11 ミトス・ファーマシューティカルズ・インコーポレーテッド 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
FR2857264A1 (fr) * 2003-07-09 2005-01-14 Maco Pharma Sa Procede d'inactivation photodynamique des pathogenes au moyen d'ala
GB0424833D0 (en) 2004-11-10 2004-12-15 Photocure Asa Method
US8585707B2 (en) 2006-06-07 2013-11-19 Gary S. Rogers Continuous low irradiance photodynamic therapy method
US20080164224A1 (en) * 2007-01-04 2008-07-10 Whirlpool Corporation System for connecting mechnically dissimilar consumer electronic devices to an adaptor or a host
EP2644228A1 (de) 2007-06-27 2013-10-02 The General Hospital Corporation Verfahren und Vorrichtung zur optischen Unterdrückung der photodynamischen Therapie
US20090062724A1 (en) * 2007-08-31 2009-03-05 Rixen Chen System and apparatus for sonodynamic therapy
US8835104B2 (en) * 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
US9402866B2 (en) 2011-04-07 2016-08-02 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4961920A (en) * 1988-12-08 1990-10-09 Luminis Pty, Ltd. Phototherapeutic monovinyl and divinyl ether-linked dimers
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses

Also Published As

Publication number Publication date
ES2160600T3 (es) 2001-11-16
NO951066D0 (no) 1995-03-20
US5736563A (en) 1998-04-07
GR3036479T3 (en) 2001-11-30
EP0660712B1 (de) 2001-05-30
CA2144327A1 (en) 1994-03-31
IL107035A0 (en) 1993-12-28
FI951295L (fi) 1995-05-17
JP3598306B2 (ja) 2004-12-08
NO951066L (no) 1995-05-19
WO1994006424A1 (en) 1994-03-31
JPH08501301A (ja) 1996-02-13
IL107035A (en) 1998-12-27
NZ255302A (en) 2001-04-27
PT660712E (pt) 2001-11-30
TW241204B (de) 1995-02-21
US5484803A (en) 1996-01-16
DK0660712T3 (da) 2001-08-27
PL308116A1 (en) 1995-07-24
FI951295A0 (fi) 1995-03-20
AU681088B2 (en) 1997-08-21
DE69330277T2 (de) 2002-04-18
HU220251B (hu) 2001-11-28
SK35295A3 (en) 1996-05-08
AU4940593A (en) 1994-04-12
ZA936968B (en) 1994-04-12
EP0660712A1 (de) 1995-07-05
CA2144327C (en) 2002-08-06
JP2001316288A (ja) 2001-11-13
FI951295A7 (fi) 1995-05-17
HUT70966A (en) 1995-11-28
DE69330277D1 (de) 2001-07-05

Similar Documents

Publication Publication Date Title
ATE201596T1 (de) Transkutane in-vivo aktivierung von photoempfindlichen mitteln im blut
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
BG43852A3 (en) Herbicide means and method for controlling of unwated vegetation
NZ503340A (en) Treatment for hairy hoof warts (papiliomatous digital dermatitis, or PDD)
EP0676954A4 (de) Hiv-lockvirus.
EP0597728A3 (de) Implantierbarer Herzschrittmacher dessen AV Verzögerung die Herzkammerreizung bestimmt.
RU93056633A (ru) Антиаллергическая композиция для лечения глаз или носа
DE69623390D1 (de) Aktive implantierbare medizinische Vorrichtung, insbesondere Herzschrittmacher oder Defibrillator
MX9407876A (es) Formulaciones de hongos entomopatogenos para uso como insecticidas biologicos.
NO961550D0 (no) Fremgangsmåte og preparat for ökning av biocidisk aktivitet
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
BE902199A (fr) Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
CH682541A5 (de) Biochemische Inaktivierung von RNA-Viren.
ATE146034T1 (de) Insektizide zusammensetzung
AU656141B2 (en) Processes and agents for combating fleas
DE69724767D1 (de) Pestizid das einen photosensibilisator und einen lockstoff enthält
EA199700297A1 (ru) Новый способ борьбы с насекомыми
DE69421253D1 (de) Feste insectizide Formulierung
ATE296118T1 (de) Photodynamische behandlung und uv-b- bestrahlung einer thrombozyten-suspension
EP1007032A4 (de) 4-cyano-4-deformylsordarizin-derivate
ATE381345T1 (de) Alpha-emittierende konstrukte sowie deren verwendung
RU96118110A (ru) Предупреждение разрушения эритроцитов, стерилизованных фталоцианином и светом в присутствии витамина e и его производных
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
IT8920322A0 (it) Procedimento di lotta biologica contro l'insetto distruttore di colture plutella xylostella utilizzante una poliedrosi nucleare e almeno un piretrinoide di sintesi.
RU95103472A (ru) Способ лечения заразных форм сифилиса

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
REN Ceased due to non-payment of the annual fee